STAAR SURGICAL CO

STAAR Surgical Company held its 2026 Annual Meeting of Shareholders where several key proposals were approved. Shareholders voted to approve Amendment No. 2 to the Amended and Restated Omnibus Equity Incentive Plan, increasing the number of shares reserved for issuance by 3,900,000. Additionally, seven directors were elected, BDO USA, P.C. was ratified as the independent registered public accounting firm, and the compensation of named executive officers was approved on an advisory basis.

STAAR SURGICAL CO (STAA) announced changes to its executive compensation. The Compensation Committee approved an increase in the annual base salary for Interim Co-CEO and CFO Deborah Andrews from $512,000 to $575,000, effective June 8, 2026. Additionally, her target annual cash bonus was raised from 55% to 60% of her base salary. These adjustments reflect a review of market compensation data and Ms. Andrews' contributions to the company's strategic and operational objectives.

STAAR Surgical Company reported a significant financial turnaround for the first quarter ended April 3, 2026, with net sales more than doubling and the company swinging to a net profit from a substantial loss in the prior year. The company incurred merger transaction and related costs of $6.7 million, while restructuring charges significantly decreased. Despite increased cash usage in operating activities, total stockholders' equity saw an increase.

STAAR Surgical reported strong first-quarter 2026 results, with net sales reaching a record $93.5 million, a 119.6% increase year-over-year. The company returned to profitability, posting a net income of $5.2 million and adjusted EBITDA of $24.4 million, a significant turnaround from a net loss in the prior year. Key drivers included a recovery in China with the successful launch of EVO+ ICL and double-digit U.S. net sales growth, alongside improved gross margins and disciplined expense management.

STAAR Surgical Company announced the termination of its merger agreement with Alcon in January 2026 following shareholder rejection, leading to a significant corporate reset. The company expanded its Board to seven directors, appointing three new members, and transitioned to an Interim Co-Chief Executive Officer structure. STAAR outlined its 2026 strategic imperatives focused on renewed revenue growth, improved profitability, and accelerated innovation, building on recent operational successes like the EVO+ launch in China and expanded EVO indications.

STAAR Surgical Company (NASDAQ: STAA) announced preliminary net sales for the first quarter ended April 3, 2026. This disclosure provides an early indication of the company's performance for the quarter. The company expects to report its full first quarter financial results in early May 2026, at which point more comprehensive financial details and management commentary will be available to investors.